The Vetr Inc. Lowers CVS Health Corp (CVS) to Buy

The Vetr Inc. Lowers CVS Health Corp (CVS) to Buy

Several other research analysts have also commented on CVS. Guggenheim reiterated a “buy” rating and set a $90.00 price target on shares of CVS Health Corp in a report on Monday, February 6th. Atlantic Securities lowered CVS Health Corp from an “overweight” rating to a “neutral” rating and set a $84.00 price target on the stock. in a report on Monday, February 6th. Deutsche Bank AG reiterated a “hold” rating and set a $88.00 price target on shares of CVS Health Corp in a report on Wednesday, February 8th. Evercore ISI reduced their price target on CVS Health Corp from $91.50 to $84.00 and set a “buy” rating on the stock in a report on Thursday, February 9th. Finally, Leerink Swann set a $90.00 price target on CVS Health Corp and gave the stock a “buy” rating in a report on Saturday, February 11th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. CVS Health Corp presently has a consensus rating of “Buy” and an average target price of $94.39.

CVS Health Corp (NYSE:CVS) was downgraded by Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Monday. They presently have a $87.97 price objective on the pharmacy operator’s stock. Vetr‘s target price would suggest a potential upside of 11.28% from the stock’s current price.

Shares of CVS Health Corp (NYSE:CVS) opened at 79.05 on Monday. The stock has a 50 day moving average of $79.23 and a 200 day moving average of $79.01. The stock has a market cap of $80.54 billion, a P/E ratio of 16.49 and a beta of 0.85. CVS Health Corp has a 52 week low of $69.30 and a 52 week high of $98.67.

In related news, EVP Troyen A. Brennan sold 23,849 shares of the company’s stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $78.73, for a total value of $1,877,631.77. Following the completion of the transaction, the executive vice president now directly owns 94,309 shares of the company’s stock, valued at $7,424,947.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David M. Denton sold 95,618 shares of the company’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $80.68, for a total value of $7,714,460.24. Following the completion of the transaction, the chief financial officer now directly owns 250,335 shares of the company’s stock, valued at $20,197,027.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 139,600 shares of company stock valued at $11,205,962. Corporate insiders own 0.58% of the company’s stock. A number of institutional investors have recently made changes to their positions in the stock. Kernodle & Katon Asset Management Group LLC increased its position in shares of CVS Health Corp by 842.3% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,404 shares of the pharmacy operator’s stock worth $110,000 after buying an additional 1,255 shares during the period. Mercer Capital Advisers Inc. acquired a new position in shares of CVS Health Corp during the first quarter worth about $118,000. SRS Capital Advisors Inc. acquired a new position in shares of CVS Health Corp during the fourth quarter worth about $120,000. D Orazio & Associates Inc. increased its position in shares of CVS Health Corp by 34.5% in the fourth quarter. D Orazio & Associates Inc. now owns 1,560 shares of the pharmacy operator’s stock worth $123,000 after buying an additional 400 shares during the period. Finally, Elgethun Capital Management acquired a new position in shares of CVS Health Corp during the fourth quarter worth about $133,000. 81.29% of the stock is owned by hedge funds and other institutional investors.

CVS Health Corp Company Profile CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “CVS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for CVS Health Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CVS Health Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment